New book by Larry Connors Click here Improve your trading - See how
(BW)(COVIDIEN)(COV.NYSE) Covidien Completes Acquisition of Power Medical Interventions Inc.
Health Editors
DUBLIN--(BUSINESS WIRE) - Sep. 08, 2009-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of Power Medical Interventions Inc. (PMI) for an aggregate consideration of approximately $65 million, including assumption of debt.
The tender offer expired at 12:00 midnight ET, at the end of September 4, 2009. At that time, the depositary for the offer advised Covidien that 15,210,583 shares of PMI had been validly tendered and not withdrawn, representing approximately 87 per cent of the outstanding PMI common shares. All shares that were validly tendered and not withdrawn were accepted for purchase and paid for in accordance with the tender offer.
An additional 247,765 shares, or approximately 1.4 per cent of the outstanding PMI shares, had been tendered pursuant to notices of guaranteed delivery.
Pursuant to the terms of the merger agreement, Covidien Delaware Corp., a wholly owned subsidiary of Covidien, exercised its option to purchase newly issued shares from PMI at the tender offer price. This permitted Covidien Delaware Corp. to acquire sufficient shares to effect a short-form merger with and into PMI, which then became a wholly owned subsidiary of Covidien.
"The acquisition of Power Medical will expand our stapling product line and is consistent with our strategy to deliver innovative healthcare solutions that enable advanced surgical care," said Scott Flora, President, Surgical Devices, Covidien. "As a pioneer in surgical stapling, we are committed to advancing healthcare technology to improve patient outcomes."
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in threesegments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2008 revenue of $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Covidien
Eric Kraus,
508-261-8305
Senior Vice President
Corporate Communications
eric.kraus@covidien.com
or Bruce Farmer,
508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or Coleman Lannum, CFA,
508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or Brian Nameth,
508-452-4363
Director
Investor Relations
brian.nameth@covidien.com
bl
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
